Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...
Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...
Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback